Home - Professionals - Jing LIU

Jing LIU

Senior Consultant
  • 010-64229007
  • liujing@ruoshanlaw.com
  • Beijing

Download CV

Professional Profile

Attorney Liu Jing previously served at the Patent Office of the China National Intellectual Property Administration (CNIPA), working in the Chemical Invention Examination Department and the Patent Reexamination Board. With seventeen years of experience at the Patent Reexamination Board, she has adjudicated numerous major and complex invalidation cases, including several of the Board's "Top Ten Cases" and high-profile cases that garnered significant attention within the industry. She specializes in invalidation and litigation cases in the chemical and pharmaceutical fields.

Attorney Liu Jing participated in the revision of the Patent Examination Guidelines (2020-2021), taking charge of amendments related to the "Pharmaceutical Patent Linkage" section. She was among the first group of "Technical Investigators for Intellectual Property Administrative Adjudication" and has led multiple research projects while frequently lecturing on the Board's Top Ten Cases. As a patent litigation attorney, she has handled several landmark cases, including those that generated substantial impact within the legal and intellectual property sectors.


Key Achievements

  • The administrative litigation dispute over the invalidation of the gold medal patent for the agent "Cinepazide"
  • The administrative litigation dispute over the invalidation of the patent for "Sorafenib" (selected by the Supreme People's Court as a publicly heard case during the 2023 Intellectual Property Awareness Week in April)
  • administrative litigation dispute over the invalidation of patents between ATL (Amperex Technology Limited) and its competitors.
  • he administrative litigation dispute over the patent invalidation case of the agent for "Upadacitinib"
  • The series of administrative adjudication cases, administrative litigation disputes, and patent invalidation cases involving the representation of the "Sofosbuvir" patent
  • The administrative litigation dispute over the invalidation of the crystalline form patent of "Rocuronium Bromide" by the agent
  • The series of invalidation disputes over the crystal form patent of "Indobufen" agents
  • The case of behavioral preservation reconsideration, patent invalidation, and administrative litigation disputes regarding the crystal form patent of "Baricitinib"
  • Representing multiple pharmaceutical companies in drug patent linkage disputes.
  • Long-term provision of patent consulting services for multiple pharmaceutical companies, including the preparation of FTO (Freedom-to-Operate) analysis reports and patent validity analysis reports.

Professional Affiliations

  • Young Committee Member of the Pharmaceutical Intellectual Property Professional Committee, Chinese Pharmaceutical Association

Licenses & Certifications

Education

Work Experience

Languages

Chinese, English